Inovio to Proceed with Phase 2 Trial of INO-4800 Vaccine Candidate for COVID-19

Inovio Announced FDA Clearance to Proceed with Trial for COVID-19 Vaccine Candidate

Inovio (INO) announced the receipt of the U.S. FDA clearance to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800, its COVID-19 vaccine candidate.
Inovio Planned Phase 2/3 INNOVATE Trial
The INNOVATE trial - a . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.